Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Investing Activities (2016 - 2025)

Voyager Therapeutics' Cash from Investing Activities history spans 11 years, with the latest figure at $47.4 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 274.33% year-over-year to $47.4 million; the TTM value through Dec 2025 reached $125.4 million, up 232.24%, while the annual FY2025 figure was $125.4 million, 232.24% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $47.4 million at Voyager Therapeutics, up from $34.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $64.4 million in Q3 2024 and bottomed at -$158.3 million in Q3 2023.
  • The 5-year median for Cash from Investing Activities is $14.2 million (2021), against an average of -$2.6 million.
  • The largest annual shift saw Cash from Investing Activities surged 1318.99% in 2021 before it tumbled 762.93% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$5.5 million in 2021, then surged by 357.45% to $14.1 million in 2022, then soared by 90.75% to $26.8 million in 2023, then plummeted by 201.38% to -$27.2 million in 2024, then surged by 274.33% to $47.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Cash from Investing Activities are $47.4 million (Q4 2025), $34.9 million (Q3 2025), and $1.9 million (Q2 2025).